Scilex Holding Co
SCLX
查看详细走势图
8.490USD
+0.630+8.02%
收盘 02/06, 16:00（美东）报价延迟15分钟
52.02M总市值
亏损市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
+8.02%
5天
-0.35%
1月
-36.40%
6月
-46.50%
今年开始到现在
-30.41%
1年
-34.21%
查看详细走势图
TradingKey Scilex Holding Co股票评分
单位: USD 更新时间: 2026-02-06操作建议
Scilex Holding Co当前公司基本面数据相对稳定，最新ESG披露属于行业领先水平。增长潜力较大。当前估值合理，在药品行业排名117/159位。机构持股占比非常高，近一月多位分析师给出公司评级为持有。最高目标价490.00。中期看，股价处于下降通道。近一个月，市场表现非常差，但基本面评分较高。目前股价在压力位和支撑位之间，可以做区间波段操作。
Scilex Holding Co评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
公司舆情
过去24小时
热度
过冷
过热
看空
Scilex Holding Co亮点
亮点风险
Scilex Holding Company is focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company’s commercial products include ZTlidoO (lidocaine topical system) 1.8% for the relief of neuropathic pain associated with postherpetic neuralgia (PHN); ELYXYB, a ready-to-use oral solution for the acute treatment of migraine, with or without aura, in adults; and GLOPERBA, the liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults. In addition, it focuses on product candidates, including SP-102 (10 mg, dexamethasone sodium phosphate viscous gel) (SEMDEXAO), an epidural injections formulation to treat lumbosacral radicular pain, or sciatica; SP-103 (lidocaine topical system) 5.4%, a ZTlido formulation, for the treatment of acute pain; and SP-104 (4.5 mg, low-dose naltrexone hydrochloride delayed-release capsules) (SP-104) for fibromyalgia treatment.
业绩高增长
公司营业收入稳步增长，连续3年增长48.79%
业绩增长期
公司处于发展阶段，最新年度总收入56.59M美元
利润高增长
公司净利润处于行业前列，最新年度总收入56.59M美元
估值高估
公司最新PE估值-0.27，处于3年历史高位
机构加仓
最新机构持股1.24M股，环比增加17.42%
先锋集团持仓
明星投资者先锋集团持仓，最新持仓市值295.02K
分析师目标
根据
1
位分析师
持有
评级
490.000
目标均价
+3319.40%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
Scilex Holding Co新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
Scilex Holding Co简介
Scilex Holding Company is focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company’s commercial products include ZTlidoO (lidocaine topical system) 1.8% for the relief of neuropathic pain associated with postherpetic neuralgia (PHN); ELYXYB, a ready-to-use oral solution for the acute treatment of migraine, with or without aura, in adults; and GLOPERBA, the liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults. In addition, it focuses on product candidates, including SP-102 (10 mg, dexamethasone sodium phosphate viscous gel) (SEMDEXAO), an epidural injections formulation to treat lumbosacral radicular pain, or sciatica; SP-103 (lidocaine topical system) 5.4%, a ZTlido formulation, for the treatment of acute pain; and SP-104 (4.5 mg, low-dose naltrexone hydrochloride delayed-release capsules) (SP-104) for fibromyalgia treatment.
公司代码SCLX
公司Scilex Holding Co
CEOJi (Henry H)
网址https://www.scilexholding.com/
相关品种
